Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04810169
Other study ID # APHP200937
Secondary ID 2020-A02722-37
Status Recruiting
Phase
First received
Last updated
Start date December 10, 2021
Est. completion date June 2023

Study information

Verified date October 2022
Source Assistance Publique - Hôpitaux de Paris
Contact David DRUMMOND, MD, PhD
Phone +33 1 44 49 48 48
Email david.drummond@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Asthma is the most common chronic disease in children. The management of asthma attacks at home is based on asthma action plans that are very heterogeneous and reflect the diversity of recommendations on this subject. The purpose of this study is to observe using smartinhalers how children and their families use their emergency treatment at home in case of asthma symptoms and asthma attacks, to allow building new recommendations based not only on the literature, but also on real-world data.


Description:

Asthma is the most common chronic disease in children. Asthma exacerbations are responsible for many unscheduled consultations by paediatricians and general practitioners, numerous emergency room visits and frequent hospitalizations Asthma action plans are documents given to families and schools to give the actions to be taken in the event of an asthma attack occurring in the family or school environment. They are recommended by all learned societies, because, combined with patient education and regular consultations, they reduce the need for unscheduled care. The main drug in the action plan is the emergency treatment, i.e. a short-acting bronchodilator (SABA). However, the doses of SABA to be used vary widely depending on the recommendations. For children up to 5 years of age, the international board of the Global Initiative for Asthma (GINA) suggests limiting the home dose to 2 puffs of 100μg every 20 minutes, to be repeated twice before consulting a physician if there is no improvement. This dose is increased to 4-10 puffs every 20 minutes in children 6 years and older. The British Thoracic Society in the United Kingdom advises administering salbutamol puffs one at a time, 30 to 60 seconds apart, until symptoms improve, with a maximum of 10 puffs. In France, the Groupe de Recherche sur les Avancées en PneumoPédiatrie (GRAPP) recommends to administer higher doses of salbutamol at home, up to one puff per 2 kg of weight, with a maximum of 10 to 15 puffs, to be repeated every 20 minutes for one hour, before giving oral corticosteroids. These very heterogeneous protocols reflect the diversity of doses proposed in the literature, and the paucity of clinical research data that makes it impossible to determine whether one approach is better than another. A study that looked at the goals of parents of children with asthma highlighted that this heterogeneity of practices is a source of stress for families: "I would like one plan and not ten" explained one parent; "I would like a plan that doesn't change all the time" reported another. Harmonization of practices is necessary in order to provide families and school physicians nurses with a consistent approach.. The aim of this study is therefore to observe, using inhalers connected to salbutamol inhalers (smart inhalers), how families manage an asthma exacerbation at home, and to integrate these data into the establishment of future recommendations.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date June 2023
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 3 Years to 11 Years
Eligibility Inclusion Criteria: - Parent of 18 years or more - Parent with a smartphone compatible with a smart inhaler - Parent with child who : - is 3 years to 11 years 11 months old - has physician-diagnosed asthma diagnosis - has a prescription of emergency treatment in case of asthma symptom - Non-opposition of the legal guardian Exclusion Criteria: - Refuse to participate at the study - Difficulty reading and/or understanding French language - Technical problem (malfunction) with the smart inhalers and/or the associated mobile application during the initial test with the parent's smartphone

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Smart inhaler
Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given

Locations

Country Name City State
France Hôpital Necker-Enfants malades Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (3)

Heidi M, Emily K, Benjamin H, Michael C, Robert K, Mitch B, Chris G, Mando W, Andrew B. Patient reported outcomes for preschool children with recurrent wheeze. NPJ Prim Care Respir Med. 2019 Mar 26;29(1):7. doi: 10.1038/s41533-019-0120-3. — View Citation

Marguet C, Michelet I, Couderc L, Lubrano M. [Management of acute asthma exacerbation in childhood: French recommendations]. Arch Pediatr. 2009 Jun;16(6):505-7. doi: 10.1016/S0929-693X(09)74046-1. French. — View Citation

Pinnock H, Parke HL, Panagioti M, Daines L, Pearce G, Epiphaniou E, Bower P, Sheikh A, Griffiths CJ, Taylor SJ; PRISMS and RECURSIVE groups. Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC Med. 2017 Mar 17;15(1):64. doi: 10.1186/s12916-017-0823-7. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mean number of actuations of the emergency treatment in the group "symptom improvement" Mean number of actuations in asthma attacks asthma attack for which parents think that the emergency treatment has been effective (group "symptom improvement"), for each symptom or symptom association 18 months
Primary Mean duration between two actuations of the emergency treatment in the group "symptom improvement" Mean duration between two actuations in asthma attacks for which parents think that the emergency treatment has been effective (group "symptom improvement"), for each symptom or symptom association 18 months
Secondary Mean number of actuations of the emergency treatment between the groups "symptom improvement" and "no improvement" Mean number of actuations for each symptom or symptom association, between asthma attack for which parents think that the emergency treatment has been effective (group "symptom improvement"), and asthma attacks for which parents think that the emergency treatment has not been effective (group "no improvement") 18 months
Secondary Mean duration between two actuations of the emergency treatment between the groups "symptom improvement" and "no improvement" Mean duration between actuations for each symptom or symptom association, between asthma attack for which parents think that the emergency treatment has been effective (group "symptom improvement"), and asthma attacks for which parents think that the emergency treatment has not been effective (group "no improvement") 18 months
Secondary Percentage of asthma attacks treated according to each guideline Percentage of asthma attacks treated following the GINA guidelines (2 puffs every 10 min), the BTS guidelines (1 puff every 30 seconds with a maximum of 10 puffs), the French guidelines (1 puff/2kg every 20 minutes) 18 months
Secondary Percentage of asthma attacks treated according to the asthma action plan of families For families with an asthma action plan provided by their physician, the percentage of asthma attacks treated by parents according to their asthma action plan will be presented, providing an evaluation of the adherence of families to their asthma action plan. 18 months
Secondary Overtreatment by families For families with an asthma action plan provided by their physician, estimate the percentage of asthma attacks treated with = 150% of the number of puffs prescribed by their physician (for example, the physician prescribed 5 puffs, the child was provided 8 puffs or more). 18 months
Secondary Undertreatment by families For families with an asthma action plan provided by their physician, estimate the percentage of asthma attacks treated with = 50% of the number of puffs prescribed by their physician (for example, the physician prescribed 5 puffs, the child was provided 2 puffs or less 18 months
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device